Taro Pharmaceuticals announced the voluntary recall of 2 lots of Phenytoin Oral Suspension 125mg/mL packaged in 237mL bottles that may not resuspend properly when shaken, which can potentially result in under or overdosing.
The Food and Drug Administration (FDA) has accepted for review the New Drug Application for Libervant® (diazepam; Aquestive Therapeutics) buccal film for the management of seizure clusters.
Epidiolex is currently approved in the US to treat seizures associated with Lennox-Gastaut syndrome and Dravet syndrome.
Road proximity is associated with an increased incidence of specific neurologic disorders.
The FDA has expanded the approval of vigabatrin to include treatment of refractory complex partial seizures in patients aged 2 to <10 years of age.
The FDA has approved Valtoco (diazepam nasal spray; Neurelis) for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity that are distinct from a patient’s usual seizure pattern in patients with epilepsy 6 years of age and older.
Taro Pharmaceuticals announced the voluntary recall of 1 lot of lamotrigine 100mg tablets to the consumer level due to cross-contamination with a small amount of enalapril maleate.
Researchers established a prediction model based on the additive effect of 4 independent factors that form an accurate model for predicting the risk of drug-resistant epilepsy in children with cerebral palsy.
Among infants breastfed by mothers who are receiving drug therapy for epilepsy, antiepileptic drug (AED) concentrations in infant blood samples are substantially lower than those in maternal blood samples.
This study described data collected from patients who self-selected to participate in the Cleveland Clinic Epilepsy Center’s virtual follow-up program.